| Brooke Revell Sansom, APRN | |
|
19611 Fl-20 West, Blountstown, FL 32424 | |
| (850) 674-5645 | |
| Not Available |
| Full Name | Brooke Revell Sansom |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 19611 Fl-20 West, Blountstown, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932741840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 9435556 (Florida) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 11015583 (Florida) | Primary |
| Entity Name | Florida Department Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932149531 PECOS PAC ID: 3072424282 Enrollment ID: O20050924000116 |
News Archive
"Where does it hurt?" is the first question asked to any person in pain. A new UCL study defines for the first time how our ability to identify where it hurts, called "spatial acuity", varies across the body, being most sensitive at the forehead and fingertips.
Though researchers are becoming increasingly aware of the long-term effects of head injury, few studies have looked at the prevalence of traumatic brain injury (TBI) in all age groups, including males and females, taking into account both mild and serious events. In a recent study published in Epidemiology, Mayo Clinic researchers applied a new, refined system for classifying injuries caused by force to the head and found that the incidence of traumatic brain injury is likely greater than has been estimated by the Centers for Disease Control and Prevention.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more organizations, including the first historically black college and university medical school and a fourth hospital in Taiwan.
Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.
› Verified 2 days ago
| Entity Name | Florida Department Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548263114 PECOS PAC ID: 3072424282 Enrollment ID: O20100518000300 |
News Archive
"Where does it hurt?" is the first question asked to any person in pain. A new UCL study defines for the first time how our ability to identify where it hurts, called "spatial acuity", varies across the body, being most sensitive at the forehead and fingertips.
Though researchers are becoming increasingly aware of the long-term effects of head injury, few studies have looked at the prevalence of traumatic brain injury (TBI) in all age groups, including males and females, taking into account both mild and serious events. In a recent study published in Epidemiology, Mayo Clinic researchers applied a new, refined system for classifying injuries caused by force to the head and found that the incidence of traumatic brain injury is likely greater than has been estimated by the Centers for Disease Control and Prevention.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more organizations, including the first historically black college and university medical school and a fourth hospital in Taiwan.
Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brooke Revell Sansom, APRN 19611 Fl-20 West, Blountstown, FL 32424 Ph: (850) 674-5645 | Brooke Revell Sansom, APRN 19611 Fl-20 West, Blountstown, FL 32424 Ph: (850) 674-5645 |
News Archive
"Where does it hurt?" is the first question asked to any person in pain. A new UCL study defines for the first time how our ability to identify where it hurts, called "spatial acuity", varies across the body, being most sensitive at the forehead and fingertips.
Though researchers are becoming increasingly aware of the long-term effects of head injury, few studies have looked at the prevalence of traumatic brain injury (TBI) in all age groups, including males and females, taking into account both mild and serious events. In a recent study published in Epidemiology, Mayo Clinic researchers applied a new, refined system for classifying injuries caused by force to the head and found that the incidence of traumatic brain injury is likely greater than has been estimated by the Centers for Disease Control and Prevention.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more organizations, including the first historically black college and university medical school and a fourth hospital in Taiwan.
Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.
› Verified 2 days ago
Linda S Deese, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 20370 Ne Burns Ave, Blountstown, FL 32424 Phone: 850-237-3000 Fax: 850-237-3001 | |
Mr. Michael B. Mckenzie, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 19611 Sr 20 W, Blountstown, FL 32424 Phone: 850-674-5645 Fax: 850-674-5420 | |
Rita Smith, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 19611 Sr 20 W, Blountstown, FL 32424 Phone: 850-674-5645 | |
Mrs. Hayley Sumner Nichols, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 16729 Sw Gaskin St, Blountstown, FL 32424 Phone: 850-643-8001 | |
Mr. Robert Casey Dobson, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 20370 Ne Burns Ave, Blountstown, FL 32424 Phone: 850-674-5411 | |
Tina Denice Dorsey, APRN-FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 20274 Central Ave W, Blountstown, FL 32424 Phone: 850-353-7689 Fax: 850-674-8889 | |
Leah Michelle Varieur, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 17808 Ne Charlie Johns St, Blountstown, FL 32424 Phone: 850-674-4524 Fax: 850-674-2300 |